The Hers website arranged on a laptop on Wednesday, February 12, 2025 in New York, US.
Gabby Jones | Bloomberg | Getty images
Snow and its health On Wednesday announced that it would offer generic semaglutide in Canada Novo nordiskThe patent on its branded drugs ozmpic and vegovi is ready to end in January.
“Canada is a major opportunity to show that in a press release, Andrew Dadam, co-founder and CEO of HIMS & Hers, said,” to show what can be seen as a cheap, high quality weight loss care. ” “” As the generic semaglutide is available globally for the first time, we focus on making it really accessible, by combination with reliable, power with personal care. ”
A telehaalth platform is included in a growing list of hospitals, drug manufacturers who are looking at Novo Nordisk’s GLP -1S to capitalize on Novo Nordisk’s laps patents. This is the first time the company will work in Canada.
Generic is essentially a brand-name copies of the drug, such as ozmpic or vegovi, which provides the same efficacy, follow the same safety standards and is allowed once the patent ends. These drugs are different from mixed versions of drugs, which are individual remedies that are converted into form or are provided in different dosage levels compared to commercially available doses.
According to the Market Research firm, the Canadian Semglutide market generated a revenue of $ 1.18 billion in 2024 and is expected to reach $ 4.03 billion by 2035. Grand view research,
There is still no common version of semaglutide on the market that has been approved by the Canadian Health Agency, but the approval process for some in the industry has begun.
Sandoz, a global leader in generic medicine manufacturing, Told science In early June it was filed for approval of a general version of Semaglutide with the Canadian regulatory agency. Health CanadaHIMS did not say in its announcement whether he has launched a uniform application for reviews, but noted that it is working with “a approved partner” to ensure that it is following all local laws and rules.
Some in the industry have expressed concern about giving Novo their patent lapse, and it comes as Vegovi Lost ground To Ellie lilyRividity treatment in the US, Zepbound, but a spokesman of the company told CNBC that all intellectual property decisions are “carefully considered,” the duration of specificity for that “pharmaceutical products may end as part of their general life cycle and normal treatment, it may be available over time.”
This announcement of HIMS follows the company’s recent conclusion acquisition Of European Telehaalth platform ZavaWhich expands the health platform in Ireland, France and Germany in Europe.
It also comes after Novo Nordisk Ended your cooperation With Hims & Hirs, the company’s sale and their weight loss drug vegovi cite concerns about promoting cheap knockoffs.
How Novo lost his Canadian patent
According to the documents filed with Canadian patent databaseNovo conducted a patent for Semaglutide, but the company last paid the annual maintenance fee.
Novo Nordisk’s lawyers requested the corresponding for the maintenance fee of $ 250 Canadian dollars ($ 185) as the company wanted more time to see if he wanted to pay it, according to the letters involved in the documents.
Two years later, the office sent a letter stating that the fee, which now involves a late charge, was not obtained by the scheduled fixed date, which brings the total to $ 450.
Novo Nordisk had a one -year grace period to pay, but never did, and so its patent missed in Canada. It was not received in 2020 when the fee was not received, but it does not end until January.
Canadian officials confirmed in their correspondence that “it could not be revived once a patent is a patent.”
“Cheap, overall obesity treatment accessible helps to help strengthen the local healthcare system and unlock millions of Canadians, to stay healthy, to fulfill the ability to fulfill more lives,” David Meenartz said, he and General Manager of International Business in Hars.
